About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Aimovig Pregnancy Exposure Registry | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNCT06150781

Aimovig Pregnancy Exposure Registry

The primary objective of this study is to estimate the proportion of major congenital malformations in infants of women with migraine exposed to erenumab-aooe during pregnancy compared to infants of w...

Lead sponsor: Amgen•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

Amgen Call Center

CONTACT

866-572-6436 medinfo@amgen.com

Sponsors

Lead Sponsor

Amgen

Age

18 - 99 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•Age 18 years or older (at time of signing the informed consent)
•Currently pregnant
•The outcome of the pregnancy must not be known
•Confirmed clinical diagnosis of migraine

Exclusion Criteria

•Women currently participating in another investigational device or investigational drug study, currently taking an investigational medicinal product, or having taken an investigational product within 3 months prior to last menstrual period (LMP) or during pregnancy. Other investigational procedures while participating in this study are excluded.
•Women exposed to any medications that target the calcitonin gene-related peptide (CGRP) pathway (ie, CGRP monoclonal antibody \[mAb\] or gepants) in the period from 5 half-lives prior to LMP through the end of pregnancy.

Related studies

MMA Embolization for Refractory Chronic Migraine

NCT06735833 · Migraine

RECRUITINGPhase 3

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

NCT06810505 · Chronic Migraine

RECRUITINGPhase 3

Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

NCT06241313 · Migraine

New Methods for Evaluating Preventive Migraine Treatment

NCT07071506 · Migraine, Migraine With or Without Aura, and more

RECRUITINGPhase 3

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

NCT07018713 · Chronic Migraine

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 4, 2025Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment2,842

Start dateJan 2021

Last updatedNov 4, 2025

Condition

Locations shown

IQVIA Virtual Site

Durham, North Carolina

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 4, 2025Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions